Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates
Provided By Globe Newswire
Last update: Oct 11, 2022
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio
The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines
Read more at globenewswire.comBlackRock Technology and Private Equity Term Trust
NYSE:BTX (2/21/2025, 8:04:35 PM)
After market: 7.64 -0.02 (-0.26%)7.66
-0.2 (-2.54%)
Find more stocks in the Stock Screener
